Compare GLAS & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLAS | CSTL |
|---|---|---|
| Founded | N/A | 2007 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 836.9M | 722.8M |
| IPO Year | 2021 | 2019 |
| Metric | GLAS | CSTL |
|---|---|---|
| Price | $7.85 | $34.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $45.50 |
| AVG Volume (30 Days) | ★ 562.5K | 275.5K |
| Earning Date | N/A | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $344,229,000.00 |
| Revenue This Year | N/A | $2.42 |
| Revenue Next Year | N/A | $12.69 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.66 |
| 52 Week Low | $7.70 | $17.72 |
| 52 Week High | $12.70 | $44.28 |
| Indicator | GLAS | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 33.11 | 58.21 |
| Support Level | $7.70 | $22.88 |
| Resistance Level | $8.41 | $42.03 |
| Average True Range (ATR) | 0.42 | 1.44 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 14.89 | 57.86 |
Glass House Brands Inc is an integrated cannabis company that operates exclusively in the state of California. Its portfolio of brands includes Glass House Farms, Forbidden Flowers, and Mama Sue Wellness. It cultivates, manufactures, and distributes cannabis bulk flower and trim to wholesalers and consumer packaged goods to third-party retail stores. It also owns and operates retail cannabis stores in the state of California. It has three reportable segments: Retail, Wholesale Biomass, and Cannabis-related consumer packaged goods. It generates the majority of its revenue from the Wholesale Biomass segment.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.